SCHEMBL6490125

SCHEMBL6490125

Cc1oc2ccccc2c1C(=O)c1cc(C(C)C)c(O)c(C(C)C)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EYA3 Q99504 8/20 0.69
CYP2C19 P33261 7/20 0.69
CYP2C9 P11712 5/20 0.57
GABRA1 P14867 1/20 0.56
GABRB1 P18505 1/20 0.56
THRB P10828 2/20 0.51
THRA P10827 1/20 0.51
LMNA P02545 3/20 0.48
MEN1 O00255 2/20 0.48
ABCB11 O95342 2/20 0.48
TTR P02766 2/20 0.48
PGR P06401 2/20 0.48
ADRA2A P08913 2/20 0.48
TBXA2R P21731 2/20 0.48
OPRM1 P35372 2/20 0.48
SLC6A3 Q01959 2/20 0.48
KMT2A Q03164 2/20 0.48
BIRC5 O15392 1/20 0.48
HTR1A P08908 1/20 0.48
DRD1 P21728 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480569 0.86 CYP2C19 (0.61) EYA3CYP2C19CYP2C9THRBTHRA
SCHEMBL6737999 0.83 EYA3 (0.71) EYA3CYP2C19CYP2C9GABRA1GABRB1
SCHEMBL6574630 0.82 GABRA1 (0.51) EYA3CYP2C19CYP2C9GABRA1GABRB1
SCHEMBL3219908 0.82 EYA3 (1.00) EYA3CYP2C19CYP2C9THRBTHRA
SCHEMBL6482824 0.81 THRA (0.72) EYA3CYP2C19CYP2C9THRBTHRA
SCHEMBL27586552 0.78 CYP2C19 (0.64) EYA3CYP2C19CYP2C9THRBTHRA
SCHEMBL28245008 0.78 CYP2C19 (0.79) EYA3CYP2C19CYP2C9THRBTHRA
SCHEMBL8994710 0.77 CYP2C19 (1.00) EYA3CYP2C19CYP2C9THRBTHRA
SCHEMBL28245012 0.75 CYP2C19 (0.79) EYA3CYP2C19CYP2C9THRBTHRA
SCHEMBL6482244 0.73 THRA (0.51) EYA3CYP2C19CYP2C9THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065208-A1 Benzofuranes and their use in the treatment of atrial fibrillation KARO BIO AB (SE) 2005-03-24 US claimed
CN-1533274-A Benzofuranes and their use in treatment of artrial fibrillation �����ɷ� 2004-09-29 CN claimed
EP-1408958-A1 BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION KARO BIO AB (SE) 2004-04-21 EP claimed
WO-2003009839-A1 BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION KARO BIO AB (SE) 2003-02-06 WO claimed
US-20050065208-A1 Benzofuranes and their use in the treatment of atrial fibrillation KARO BIO AB (SE) 2005-03-24 US disclosed
CN-1533274-A Benzofuranes and their use in treatment of artrial fibrillation �����ɷ� 2004-09-29 CN disclosed
EP-1408958-A1 BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION KARO BIO AB (SE) 2004-04-21 EP disclosed
WO-2003009839-A1 BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION KARO BIO AB (SE) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065208-A1 Benzofuranes and their use in the treatment of atrial fibrillation KCNH1, KCNJ2, KCNQ2 EYA3 3572/4885CYP2C19 240/4885CYP2C9 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.